ID23900A - Turunan-turunan dolastatin-15 dalam kombinasi dengan taksana - Google Patents

Turunan-turunan dolastatin-15 dalam kombinasi dengan taksana

Info

Publication number: ID23900A
Authority: ID; Indonesia
Prior art keywords: combination; taxation; dolastatin; designs; compounds
Prior art date: 1997-03-13

Application number

IDW991020A

Other languages

English (en)

Inventor

Andreas Haupt

Teresa Barlozzari

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-13

Filing date

1998-03-09

Publication date

2000-05-25

1998-03-09 Application filed by Basf Ag filed Critical Basf Ag

2000-05-25 Publication of ID23900A publication Critical patent/ID23900A/id

Links

LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 title 1
LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 title 1
108010045552 dolastatin 15 Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000001093 anti-cancer Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

IDW991020A 1997-03-13 1998-03-09 Turunan-turunan dolastatin-15 dalam kombinasi dengan taksana ID23900A (id)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/819,101 US6103698A (en)	1997-03-13	1997-03-13	Dolastatin-15 derivatives in combination with taxanes

Publications (1)

Publication Number	Publication Date
ID23900A true ID23900A (id)	2000-05-25

Family

ID=25227196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW991020A ID23900A (id)	1997-03-13	1998-03-09	Turunan-turunan dolastatin-15 dalam kombinasi dengan taksana

Country Status (29)

Country	Link
US (2)	US6103698A (id)
EP (1)	EP0981358B1 (id)
JP (1)	JP2001514659A (id)
KR (1)	KR100555604B1 (id)
CN (1)	CN1157223C (id)
AT (1)	ATE241376T1 (id)
AU (1)	AU728027B2 (id)
BG (1)	BG64338B1 (id)
BR (1)	BR9808249A (id)
CA (1)	CA2282720C (id)
CO (1)	CO4940498A1 (id)
CZ (1)	CZ293905B6 (id)
DE (1)	DE69815100T2 (id)
DK (1)	DK0981358T3 (id)
ES (1)	ES2200317T3 (id)
HR (1)	HRP980125A2 (id)
HU (1)	HU228860B1 (id)
ID (1)	ID23900A (id)
IL (2)	IL131597A0 (id)
NO (1)	NO323894B1 (id)
NZ (1)	NZ337416A (id)
PL (1)	PL197834B1 (id)
PT (1)	PT981358E (id)
RU (1)	RU2218174C2 (id)
SK (1)	SK285133B6 (id)
TR (1)	TR199902244T2 (id)
TW (1)	TWI277426B (id)
WO (1)	WO1998040092A1 (id)
ZA (1)	ZA982093B (id)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010009901A1 (en) *	1996-12-11	2001-07-26	Basf Aktiengesellschaft Germany	Antineoplastic peptides
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20050192443A1 (en) *	2000-11-08	2005-09-01	Lorus Therapeutics Inc.	Biological response modifier for the treatment of cancer
EP1333847A1 (en) *	2000-11-08	2003-08-13	Lorus Therapeutics Inc.	Combination preparation of a biological response modidier and an anticancer agent and uses thereof
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
SG10201407457UA (en)	2006-05-16	2014-12-30	Pharmascience Inc	Iap bir domain binding compounds
US9173961B2 (en)	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
MX340870B (es)	2010-02-12	2016-07-27	Pharmascience Inc	Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
TW202210498A (zh) *	2020-06-03	2022-03-16	日商中外製藥股份有限公司	高難度序列之有效率的胜肽縮合法
EP4400121A1 (en)	2021-09-03	2024-07-17	Toray Industries, Inc.	Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US5676978A (en)	1989-02-14	1997-10-14	Amira, Inc.	Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) *	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
SG87056A1 (en)	1991-08-09	2002-03-19	Teikoku Hormone Mfg Co Ltd	Novel tetrapeptide derivative
US5227400A (en) *	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) *	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) *	1992-02-13	1993-12-21	Bristol-Myers Squibb Company	Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) *	1992-03-13	1994-05-06	Rhone Poulenc Rorer Sa	Procede de preparation de derives du taxane.
US5831002A (en) *	1992-05-20	1998-11-03	Basf Aktiengesellschaft	Antitumor peptides
US5248796A (en) *	1992-06-18	1993-09-28	Bristol-Myers Squibb Company	Taxol derivatives
US5254580A (en) *	1993-01-19	1993-10-19	Bristol-Myers Squibb Company	7,8-cyclopropataxanes
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
AU679479B2 (en) *	1992-12-16	1997-07-03	Basf Aktiengesellschaft	Dolostatin analog
US5484612A (en) *	1993-09-22	1996-01-16	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en)	1993-09-29	1995-03-30	George Weber	Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) *	1993-12-22	1995-09-05	Bionumerik Pharmaceuticals, Inc.	Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) *	1994-06-02	1996-02-27	Shimizu; Yuzuru	Caribenolide I
US5525613A (en) *	1994-06-16	1996-06-11	Entropin, Inc.	Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530097A (en) *	1994-08-01	1996-06-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory peptide amides
US5504191A (en) *	1994-08-01	1996-04-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide methyl esters
US5543423A (en) *	1994-11-16	1996-08-06	Vertex Pharmaceuticals, Incorporated	Amino acid derivatives with improved multi-drug resistance activity
DE69534535T2 (de)	1994-12-15	2006-07-06	Baker Norton Pharmaceuticals, Inc., Miami	Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung

1997
- 1997-03-13 US US08/819,101 patent/US6103698A/en not_active Expired - Lifetime
1998
- 1998-03-09 DK DK98909066T patent/DK0981358T3/da active
- 1998-03-09 EP EP98909066A patent/EP0981358B1/en not_active Expired - Lifetime
- 1998-03-09 SK SK1251-99A patent/SK285133B6/sk not_active IP Right Cessation
- 1998-03-09 HU HU0001381A patent/HU228860B1/hu not_active IP Right Cessation
- 1998-03-09 NZ NZ337416A patent/NZ337416A/en not_active IP Right Cessation
- 1998-03-09 ES ES98909066T patent/ES2200317T3/es not_active Expired - Lifetime
- 1998-03-09 RU RU99122032/14A patent/RU2218174C2/ru not_active IP Right Cessation
- 1998-03-09 PL PL335579A patent/PL197834B1/pl unknown
- 1998-03-09 WO PCT/US1998/004594 patent/WO1998040092A1/en not_active Ceased
- 1998-03-09 JP JP53967998A patent/JP2001514659A/ja active Pending
- 1998-03-09 DE DE69815100T patent/DE69815100T2/de not_active Expired - Lifetime
- 1998-03-09 CN CNB988033089A patent/CN1157223C/zh not_active Expired - Fee Related
- 1998-03-09 AU AU66945/98A patent/AU728027B2/en not_active Ceased
- 1998-03-09 BR BR9808249-3A patent/BR9808249A/pt not_active IP Right Cessation
- 1998-03-09 TR TR1999/02244T patent/TR199902244T2/xx unknown
- 1998-03-09 PT PT98909066T patent/PT981358E/pt unknown
- 1998-03-09 KR KR1019997008305A patent/KR100555604B1/ko not_active Expired - Fee Related
- 1998-03-09 CA CA002282720A patent/CA2282720C/en not_active Expired - Fee Related
- 1998-03-09 IL IL13159798A patent/IL131597A0/xx active IP Right Grant
- 1998-03-09 CZ CZ19993211A patent/CZ293905B6/cs not_active IP Right Cessation
- 1998-03-09 AT AT98909066T patent/ATE241376T1/de active
- 1998-03-09 ID IDW991020A patent/ID23900A/id unknown
- 1998-03-10 HR HR08/819,101A patent/HRP980125A2/hr not_active Application Discontinuation
- 1998-03-12 CO CO98013903A patent/CO4940498A1/es unknown
- 1998-03-12 ZA ZA9802093A patent/ZA982093B/xx unknown
- 1998-03-13 TW TW087103777A patent/TWI277426B/zh not_active IP Right Cessation
1999
- 1999-08-26 IL IL131597A patent/IL131597A/en not_active IP Right Cessation
- 1999-09-10 NO NO19994408A patent/NO323894B1/no not_active IP Right Cessation
- 1999-09-13 BG BG103728A patent/BG64338B1/bg unknown
2000
- 2000-03-07 US US09/520,254 patent/US6632795B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CO4940498A1 (es)	2000-07-24
HU228860B1 (en)	2013-06-28
IL131597A0 (en)	2001-01-28
AU728027B2 (en)	2001-01-04
US6103698A (en)	2000-08-15
CZ321199A3 (cs)	2000-02-16
BR9808249A (pt)	2000-05-16
KR100555604B1 (ko)	2006-03-03
TWI277426B (en)	2007-04-01
NO323894B1 (no)	2007-07-16
HRP980125A2 (en)	1999-02-28
DK0981358T3 (da)	2003-09-22
JP2001514659A (ja)	2001-09-11
NO994408L (no)	1999-11-10
PL197834B1 (pl)	2008-04-30
ATE241376T1 (de)	2003-06-15
HUP0001381A3 (en)	2001-12-28
US6632795B1 (en)	2003-10-14
IL131597A (en)	2006-06-11
RU2218174C2 (ru)	2003-12-10
PL335579A1 (en)	2000-05-08
CN1157223C (zh)	2004-07-14
SK285133B6 (sk)	2006-07-07
CZ293905B6 (cs)	2004-08-18
ES2200317T3 (es)	2004-03-01
ZA982093B (en)	1999-09-12
NO994408D0 (no)	1999-09-10
KR20000076211A (ko)	2000-12-26
WO1998040092A1 (en)	1998-09-17
HUP0001381A2 (hu)	2000-10-28
CA2282720A1 (en)	1998-09-17
HK1026851A1 (en)	2000-12-29
AU6694598A (en)	1998-09-29
PT981358E (pt)	2003-09-30
CN1252728A (zh)	2000-05-10
DE69815100D1 (de)	2003-07-03
TR199902244T2 (xx)	1999-12-21
BG64338B1 (bg)	2004-10-29
CA2282720C (en)	2009-12-29
EP0981358A1 (en)	2000-03-01
SK125199A3 (en)	2000-08-14
EP0981358B1 (en)	2003-05-28
NZ337416A (en)	2001-05-25
DE69815100T2 (de)	2004-02-05
BG103728A (en)	2000-04-28

Publication	Publication Date	Title
MX9306924A (es)	1994-05-31	Composiciones antitumorales que contienen derivados de taxano.
ES2151277T3 (es)	2000-12-16	Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
CY1105399T1 (el)	2010-04-28	Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων
ATE342054T1 (de)	2006-11-15	Verfahren und zusammansetzung zur behandlung von krebs
FI943749A0 (fi)	1994-08-15	Taksaanijohdannaisten fosfono-oksimetyylieetterit
GR3036211T3 (en)	2001-10-31	Taxane class derivative based pharmaceutical compositions
BR0213424A (pt)	2004-12-14	Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BR0104350A (pt)	2002-01-02	Taxanos de c10 acetato heterossubstituìdo como agentes antitumor
TR199800443T1 (xx)	1998-06-22	Hidroliz y�kseltici taksan hidrofobik t�revleri.
DK0981358T3 (da)	2003-09-22	Dolastatin-15-derivater i kombinationer med taxaner
ATE355837T1 (de)	2007-03-15	Antitumor-zusammensetzungen enthaltend taxan- derivate
ATE554753T1 (de)	2012-05-15	2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
EE200200087A (et)	2003-04-15	Kompositsioon hepatotsellulaarse kartsinoomi raviks
DE69430797D1 (de)	2002-07-18	C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
ATE393624T1 (de)	2008-05-15	Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
TW200719903A (en)	2007-06-01	Compositions for the treatment of neoplasms
BR0208221A (pt)	2004-03-02	Combinação de uma taxano e uma cinase dependente de ciclina
NZ514407A (en)	2004-12-24	C10 carbamoyloxy substituted taxanes as antitumor agents
DE60133600D1 (de)	2008-05-29	C7-carbamoyloxysubstituierte taxane als antitumormittel
EP0793499A4 (en)	2000-11-08	METHOD AND MEANS FOR REDUCING TUMOR DEVELOPMENT BY MEANS OF A COMBINATION OF A TAXAN COMPOUND AND A TELLUR AND / OR SELENIUM COMPOUND
SI1287854T1 (sl)	2006-08-31	Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
CA2206567A1 (en)	1996-06-20	Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound